CANCER ZERO
LIVE

Serial Number

97703809

Owner

IN8bio, Inc.

Attorney

Mark A. Jansen

Filing Date

Dec 5, 2022

Add to watchlist:

No watchlists yet
View on USPTO

CANCER ZERO Trademark

Serial Number: 97703809

CANCER ZERO is a trademark filed by IN8bio, Inc. on December 5, 2022. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

IN8bio, Inc.

350 Fifth Avenue, Suite 5330
New York, NY 10118

Entity Type: 03

Trademark Details

Filing Date

December 5, 2022

Registration Date

Not Registered

Published for Opposition

January 16, 2024

Goods & Services

Research, development, and evaluation of new products; pharmaceutical, medicine, and vaccine research and development services; technical research in the field of pharmaceutical studies; laboratory analysis and research into new drugs and pharmaceutical products; development of scientific measuring and testing methods in the field of oncology; design, development, research, and conducting clinical trials for others in connection with drugs, pharmaceuticals, and cellular therapies for the treatment and/or prevention of cancer; research and development services in the fields of oncology, immunotherapy, chemotherapy and combination therapies for the treatment of cancer and tumors; providing medical research information in the fields of oncology, immunotherapy, chemotherapy and combination therapies; scientific advisory services, namely, providing scientific information, advice and consultancy in the field of oncology; research and development in the field of bioengineering and genetic engineering; Research and development of treatments and therapies in the field of oncology; Research and development of pharmaceuticals for the treatment and prevention of cancer, autoimmune, inflammatory, and infectious diseases and disorders; Scientific research for medical purposes in the field of cancer, autoimmune, inflammatory, and infectious diseases and disorders; Molecular, cellular, and genetic research and development; Development of processes and methods for the manufacturing and engineering of cells and molecules; development of therapeutics and treatments for the prevention of cancer, autoimmune, inflammatory, genetic and infectious diseases and disorders; Development of diagnostic medical measuring and testing methods in the field of cancer therapy and treatment

Medical services; Providing health information; Providing health information in the field of bioengineering and genetic engineering; Providing health information in the field of autoimmune, inflammatory and infectious diseases and disorders, cancer prevention and treatment; Medical diagnosis and treatment of cancer, autoimmune, inflammatory, and infectious diseases and disorders

Pharmaceutical preparations, namely, oncological preparations; reagent, diagnostic and therapeutic preparations for medical use in oncology; targeted medical preparations for use in oncology; pharmaceutical preparations for use in the treatment of cancer and tumors; pharmaceutical and medicinal preparations for the treatment of cancer and oncological conditions; pharmaceutical and biological preparations for use in immunotherapies to improve immune system function; pharmaceutical and biological preparations combining immunotherapies and chemotherapies for treatments in the field of oncology; medical and veterinary preparations for the delivery of compounds to the body for the treatment and prevention of immunological and oncological diseases and disorders; pharmaceutical and biological preparations comprised of modified t cells used for multiple modes of treatment against tumor resistance and immunosuppression; pharmaceuticals in the nature of cell therapeutics for the treatment and prevention of cancer; engineered cell therapies, namely, engineered T cells, immune cells, and antibodies for the treatment and prevention of cancer

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 10, 2026 EXRA
SOU EXTENSION 4 GRANTED
Mar 9, 2026 EX4G
SOU EXTENSION 4 FILED
Mar 9, 2026 EXT4
SOU TEAS EXTENSION RECEIVED
Mar 9, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 16, 2025 EXRA
SOU EXTENSION 3 GRANTED
Jul 15, 2025 EX3G
SOU EXTENSION 3 FILED
Jul 15, 2025 EXT3
SOU TEAS EXTENSION RECEIVED
Jul 15, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 11, 2025 EXRA
SOU EXTENSION 2 GRANTED
Mar 11, 2025 EX2G
SOU EXTENSION 2 FILED
Mar 11, 2025 EXT2
SOU TEAS EXTENSION RECEIVED
Mar 11, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 9, 2024 EXRA
SOU EXTENSION 1 GRANTED
Sep 9, 2024 EX1G
SOU EXTENSION 1 FILED
Sep 9, 2024 EXT1
SOU TEAS EXTENSION RECEIVED
Sep 9, 2024 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Mar 12, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 16, 2024 NPUB
PUBLISHED FOR OPPOSITION
Jan 16, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 27, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 13, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 12, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 11, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 11, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Oct 23, 2023 GNRN
NON-FINAL ACTION E-MAILED
Oct 23, 2023 GNRT
NON-FINAL ACTION WRITTEN
Oct 23, 2023 CNRT
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Oct 23, 2023 ZZZX
WITHDRAWN FROM PUB - OG REVIEW QUERY
Oct 3, 2023 PBCR
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 19, 2023 CNSA
EXAMINER'S AMENDMENT ENTERED
Sep 19, 2023 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Sep 19, 2023 GNEN
EXAMINERS AMENDMENT E-MAILED
Sep 19, 2023 GNEA
EXAMINERS AMENDMENT -WRITTEN
Sep 19, 2023 CNEA
ASSIGNED TO EXAMINER
Sep 12, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 3, 2023 NWOS
NEW APPLICATION ENTERED
Dec 8, 2022 NWAP